不同年龄组高级别浆液性卵巢癌的胚系突变图谱:年龄只是一个数字吗?
该研究纳入2015年1月1日至2022年11月15日接受≥76基因肿瘤-正常测序的1231例高级别浆液性卵巢癌患者,分析胚系致病变异随年龄的变化。诊断年龄≤49岁、50-69岁、≥70岁组的gPV率分别为42%、27%、16%(p<0.001);调整遗传 ancestry 和NCI合并症指数后,≥70岁组发生gPV的OR为0.58(95%CI 0.38-0.86),≤49岁组OR为1.78(95%CI 1.18-2.68)。结论认为所有年龄组gPV率均较高(≥10%),无论年龄均应普遍进行基因检测。
要点
- 诊断年龄≤49岁、50-69岁、≥70岁组的胚系致病变异率分别为42%、27%、16%(p<0.001)。
- 调整混杂后,≥70岁组发生gPV的OR为0.58(95%CI 0.38-0.86),≤49岁组OR为1.78(95%CI 1.18-2.68)。
- 所有年龄组gPV率均≥10%,遗传随访和PARP抑制剂使用在各年龄组间无差异(p>0.05)。
核心结论
- 尽管gPV率随年龄变化,早发性卵巢癌患者最高,但所有年龄组gPV率均较高(≥10%),且遗传随访和靶向治疗实施情况相似,因此无论年龄,对所有卵巢癌患者进行普遍基因检测是重要的。
研究设计与样本
- 纳入2015年1月1日至2022年11月15日期间接受≥76基因临床肿瘤-正常测序的1231例高级别浆液性卵巢癌患者,收集中位诊断年龄等临床变量,采用逻辑回归模型分析gPV、年龄与临床变量之间的关联。
主要发现
- 1231例患者中位诊断年龄为63岁(范围33-93);诊断年龄≤49岁163例(13%),50-69岁739例(60%),≥70岁329例(27%)。
- 诊断年龄≤49岁、50-69岁、≥70岁组的gPV分别为68例(42%)、200例(27%)、52例(16%),p<0.001。
- 与诊断年龄50-69岁组相比,≥70岁组发生gPV的OR为0.58(95%CI 0.38-0.86),≤49岁组OR为1.78(95%CI 1.18-2.68),均经遗传祖先和NCI合并症指数调整。
- 诊断年龄≥80岁的67例患者中7例(10%)有gPV,其中2例位于卵巢癌相关基因(BRCA2、PALB2);诊断年龄≤39岁的21例患者中12例(57%)有gPV,均位于卵巢癌相关基因。
- 遗传随访或聚(ADP-核糖)聚合酶抑制剂使用在各年龄组间无差异(p>0.05)。
临床怎么用
- 作者结论认为,无论年龄,对所有卵巢癌患者进行普遍基因检测是重要的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize age-related variations in germline pathogenic variants (gPVs) in patients with high-grade serous ovarian cancer (HGSOC). METHODS: Patients with HGSOC who underwent clinical tumor-normal sequencing of ≥76 genes from 1/1/2015-11/15/2022, were included. Clinical variables including age at diagnosis were collected. Logistic regression models were built to examine associations between gPV, age, and clinical variables. RESULTS: Of 1231 patients, median age at diagnosis was 63 years (range, 33-93); 163 patients (13 %) were diagnosed at age ≤ 49, 739 (60 %) between ages 50-69, and 329 (27 %) at age ≥ 70 years. gPVs were observed in 68 (42 %), 200 (27 %), and 52 patients (16 %) respectively, p < 0.001. Compared to patients diagnosed between ages 50-69, those diagnosed at age ≥ 70 were less likely to have a gPV (OR: 0.58; 95 % CI: 0.38-0.86) and those diagnosed at age ≤ 49 were more likely to have a gPV (OR: 1.78; 95 % CI: 1.18-2.68), after adjustment for genetic ancestry and NCI Comorbidity Index. Seven of 67 patients (10 %) diagnosed at age ≥ 80 years had a gPV, including 2 in OC-related genes (BRCA2, PALB2). Twelve of 21 patients (57 %) diagnosed at age ≤ 39 years had a gPV, all in OC-related genes. No differences in genetics follow-up or poly (ADP-ribose) polymerase inhibitor use were observed by age (p > 0.05). CONCLUSION: Although gPV rates varied by age with the highest rates observed in patients with early-onset OC, rates were high (≥10 %) in all age groups, with similar genetics follow-up and implementation of targeted therapies. Universal genetic testing is important for all patients with OC regardless of age.
引用
- Sia TY, Moufarrij S, Milani J, et al. Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number? Gynecol Oncol. 2025. PMID: 40812120. doi:10.1016/j.ygyno.2025.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。